GSK Supports Waxman/Hatch Trade: Drop Bolar, Remove 30-Month Stays

GlaxoSmithKline supports a legislative deal to change the 30-month stays on generic approvals during patent litigation in return for having generic firms give up their right to do development work on drugs prior to patent expiration